Shorter Duration of Feeding Tube Placement With IMRT

This article originally appeared here.
Share this content:
Shorter Duration of Feeding Tube Placement With IMRT
Shorter Duration of Feeding Tube Placement With IMRT

FRIDAY, Sept. 30, 2016 (HealthDay News) -- For patients with head and neck cancer (HNC), the duration of feeding tube placement is shorter for those who receive definitive intensity-modulated radiation therapy (IMRT) compared with those who receive three-dimensional radiation therapy (3DRT), according to a study published online Sept. 23 in Cancer.

Beth M. Beadle, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues used the linked Surveillance, Epidemiology, and End Results-Medicare database to determine the cohort, demographics, and cancer-related variables for patients with HNC. Treatment details were analyzed using claims data.

The researchers identified 2,993 patients. Overall, 54.4 percent of patients had ever had a feeding tube placed at a median follow-up of 47 months, with a median duration of 277 days from feeding tube placement to removal. The rates of feeding tube placement were similar for patients who received IMRT and 3DRT (odds ratio, 1.10; P = 0.35); patients who received 3DRT had a feeding tube in place for significantly longer than those who received IMRT (1.18 times longer; P = 0.03). The difference was only seen for patients who received definitive RT; no significant difference was seen in feeding tube placement or duration for patients who underwent surgery and received adjuvant RT.

"These data suggest that there may be significant quality-of-life benefits to IMRT with respect to long-term swallowing function in patients with HNC," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »